The CRISPR in Agriculture Market represents a transformative sector leveraging gene editing technology to boost crop yields, enhance resilience against climate challenges, and meet escalating global food needs. The market is poised for robust expansion to 3.26 billion USD by 2030, reflecting a compound annual growth rate of 19.4%.
The CRISPR in Agriculture Market overview highlights CRISPRs role in addressing pressing agricultural issues, including population growth projected to hit 10 billion by 2050, which demands a 60% surge in food production according to World Bank estimates. Innovations integrate artificial intelligence for precise breeding, enabling traits like drought tolerance and nutritional improvements in staples such as maize and soybean. Yet, ethical debates, delivery inefficiencies, and off target effects pose hurdles, tempered by opportunities in regulatory easing and public private collaborations.
Market sizing underscores a swift trajectory, starting from 1.34 billion USD by end of 2025. Segmentation spans offerings like tools, instruments, software, services, licensing, and commercial products. CRISPR systems vary from Cas9 to Cas12 and Cas13, with editing modalities including knockouts, base edits, and insertions. Delivery methods encompass agrobacterium mediated approaches, biolistics, and viral vectors. Product types focus on seeds, biopesticides, and beyond, applied across row crops like corn and wheat, fruits, vegetables, and specialty varieties. Applications cover yield enhancement, stress tolerance, disease resistance, and livestock productivity, serving end users from research institutes to commercial farmers.
Drivers fuel this momentum, with investments in gene editing startups soaring 206 percent in early 2024 to 161 million USD, spurred by climate imperatives. Precision agriculture and AI driven analytics, dubbed Breeding 4.0, leverage drones, satellites, and multi omics data for targeted edits. Global calls from Nobel laureates underscore gene editings potential for sustainable yields amid rising demands.
Restraints include ethical qualms over genetic modifications, technical gaps in cellular delivery, and risks from unintended edits, inviting rigorous oversight. Opportunities emerge in AI integration for phenotypic automation, reforms exempting certain edits from genetically modified organism labels in Asia Pacific and Europe, and initiatives for smallholder farmers, such as flood resistant rice in Southeast Asia.
Challenges persist in scaling complex traits and navigating approval delays, particularly in cautious European markets bound by biodiversity rules. Key players like Corteva Agriscience, Bayer AG, Syngenta Group, BASF SE, and Pairwise Plants LLC dominate through partnerships and research hubs. Recent moves include Cortevas 25 million USD stake in Pairwise for resilient crops in September 2024, Bayers automated facility launch in July 2024, and Syngentas open access platform in June 2024 for academic breeders.
Competitive dynamics feature joint ventures, expansions, and R and D pushes, analyzed via SWOT, Porters Five Forces, and value chains. North America leads with policy support and investments, tackling anomalies like the 2.8 degrees Fahrenheit warmer June 2025 in the US. Europe advances moderately via sustainability aligned tools, while Asia Pacific surges fastest, backed by Chinas plans and Indias exemptions. Rest of World, including Africa, gains from training programs like the Nairobi CRISPR academy for 80 to 100 scientists over five years.
Insights reveal a sector ripe for innovation, with free report customizations up to 80 hours, covering 28 countries and 15 firms. This growth trajectory promises equitable food systems, blending technology with ecological stewardship for a resilient agricultural future.
AWS Marketplace now accepts line of credit payments through the PNC Vendor Finance program. This program is available to select AWS customers in the US, excluding NV, NC, ND, TN, & VT.
This listing offers one pricing dimension: Product Access, billed in units. It is free, so you pay nothing to gain access. There are no separate tiers, seat counts, or usage add-ons to choose from. You get access to the market analysis report through this single option. After access is granted, the report is delivered digitally, typically within 24 to 48 hours. Since only one dimension exists, pricing does not scale up or down based on quantity or usage.
Top-of-mind questions for buyers
What does one unit of Product Access grant me?
One unit grants you access to the CRISPR in Agriculture market analysis report. Access covers the digital report itself, not seats or usage-metered features. Since the product is free, adding units does not change your cost.
How and when do I receive the report after access is granted?
You receive the report in a digital format, delivered by email or download link. Reports are typically available within 24 to 48 hours after your access is confirmed. Delivery timing may vary if customization is involved.
Does my cost change if usage or the number of readers grows?
No. This listing has one dimension, Product Access, billed in units at no charge. There are no seat counts, tiers, or usage add-ons that scale your bill. Your cost stays the same regardless of how many people read the report.
www.nextmsc.com
Helpful?
Vendor refund policy
All sales are final; no refunds or returns are accepted. Our reports include sensitive, researched data from various sources, including industry experts and paid services. We ensure confidentiality and offer customization at an additional cost. Please review our terms before purchase. For inquiries, contact customer service.
How can we make this page better?
Tell us how we can improve this page, or report an issue with this product.
Give us feedbackReport a problem with this product or seller
Legal
Vendor terms and conditions
Upon subscribing to this product, you must acknowledge and agree to the terms and conditions outlined in the vendor's End User License Agreement (EULA).
Content disclaimer
Vendors are responsible for their product descriptions and other product content. AWS does not warrant that vendors' product descriptions or other product content are accurate, complete, reliable, current, or error-free.
NOTE: This deployment requires a specific SageMaker Inference AMI selection (al2-ami-sagemaker-inference-gpu-3-1). Please use the example notebook provided at https://github.com/NVIDIA/nim-deploy/blob/main/cloud-service-providers/aws/sagemaker/awsmarketplacenotebooks/nim-evo2-40b-v2-1-0awsmarketplace.ipynb for deploying the endpoint.
Evo 2 is a biological foundation model that can interpret and generate DNA sequences across various biological scales: from individual molecules to entire genomes while retaining sensitivity to single-nucleotide changes, enabling zero-shot predictions and complex biological system designs.
60-minute live analyst briefing focused on the CRISPR in Agriculture Market, helping biotechnology, agrigenomics, and agricultural leaders optimize research investments, commercialization strategies, and AWS cloud architecture using 2026–2035 market intelligence.
Expert-led strategic advisory on the Designer Phages landscape. Align your genomic sequencing, CRISPR modeling, and bioinformatics architectures securely on Amazon Web Services (AWS).
60-minute live analyst briefing focused on the Base Editing Market (2026–2035), helping biotechnology, genomics, and healthcare strategy leaders optimize AWS cloud infrastructure, AI workloads, and genomic analytics roadmaps.